Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.332.6032.907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review.
Cancer Med
February 2025
ERN-EuroBloodNet, Hôpital St Louis/Université Paris 7, Paris, France.
Introduction: Burkitt lymphoma (BL) is a rare and aggressive subtype of non-Hodgkin's lymphoma. Several studies have identified prognostic factors (PFs) for disease progression and mortality among adults with BL. However, there is no consensus on risk stratification based on PFs.
View Article and Find Full Text PDFInvasive stratified mucin-producing carcinoma of the cervix in a pregnant patient.
Int J Gynecol Cancer
January 2025
Radiodiagnóstico. Hospital Universitario de Ciudad Real, Ciudad Real, Spain.
Laparoscopic right extraperitoneal approach for caval lymph node recurrences in gynecological tumors in 10 steps.
Int J Gynecol Cancer
January 2025
Vall d'Hebron University Hospital, Gynecologic Oncology Unit, Barcelona, Spain; Hospital Universitari General de Catalunya Dexeos Mujer, Gynecology Department, Barcelona, Spain.
Key takeaways: Gynecologic cancer breakthroughs at ESMO Congress 2024.
Int J Gynecol Cancer
January 2025
Hospital 9 de Julho-Dasa Oncologia, São Paulo, Brazil.
The "Key Takeaways: Gynecological cancer breakthroughs at ESMO Congress 2024" aims to include the most original and potentially practice-changing research in gynecologic oncology presented during the Annual Congress of the European Society of Medical Oncology, held in Barcelona, Spain, September 13 to 17, 2024. The scientific program encompassed a wide range of topics across various fields within oncology, and we selected 13 studies presented during the conference considered highly significant in the field of gynecologic oncology.
View Article and Find Full Text PDFThe severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD3/CD56 NK cells against moderate/severe cases of COVID-19 (NCT04578210).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!